Heineken warns British pubs the weight-loss drug boom could lead to a drop in beer sales
Summary
Heineken has warned British bars and pubs that the boom in popularity of weight-loss drugs could lead to a fall in sales of beer and cider, The Guardian reported on Friday 23 October. The world's second largest brewer sent a presentation to British hospitality customers earlier this month warning that GLP-1 use, led by Ozempic and Wegovy, can reduce the desire to drink alcohol, which could lead to 'fullness and fewer serves' of pints in pubs and bars, according to The Guardian.
Latest: Heineken warned British bars and pubs that the boom in weight-loss drugs could lead to a fall in sales of beer and cider, The Guardian reported, the world's second largest brewer saying that drugs such as Wegovy can reduce the desire to drink alcohol, which could lead to 'fullness and fewer serves' of pints in pubs and bars.
Written automatically by an AI from the articles' headlines and descriptions. It can contain errors: follow the links to read the articles.
How it unfolded
Friday 23 October
Heineken warned British bars and pubs that the boom in weight-loss drugs could lead to a fall in sales of beer and cider, The Guardian reported, the world's second largest brewer saying that drugs such as Wegovy can reduce the desire to drink alcohol, which could lead to 'fullness and fewer serves' of pints in pubs and bars.